Neurodegenerative disorders including Parkinson’s disease (PD), Huntington’s disease
(HD) and the most frequent, Alzheimer’s disease (AD), represent one of the most urgent medical
needs worldwide. Despite a significantly developed understanding of disease development and
pathology, treatments that stop AD progression are not yet available. The recent approval of sodium
oligomannate (GV-971) for AD treatment in China emphasized the potential value of natural products
for the treatment of neurodegenerative disorders. Many current clinical studies include the
administration of a natural compound as a single and combination treatment. The most prominent
mechanisms of action are anti-inflammatory and anti-oxidative activities, thus preserving cellular
survival. Here, we review current natural products that are either approved or are in testing for a
treatment of neurodegeneration in AD. In addition to the most important compounds of plant origin,
we also put special emphasis on compounds from algae, given their neuroprotective activity and
their underlying mechanisms of neuroprotection.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:87377 |
| Date | 10 October 2023 |
| Creators | Klose, Jana, Griehl, Carola, Roßner, Steffen, Schilling, Stephan |
| Publisher | MDPI |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 694, 10.3390/biom12050694 |
Page generated in 0.0164 seconds